Progress in vaccine development during the endgame of the Global Polio Eradication Initiative

doi:10.19803/j.1672-8629.20260303

Abstract

Abstract: In the endgame of the Global Polio Eradication Initiative (GPEI), the research and development of poliovirus vaccines is shifting from empirical attenuation to molecular rational design to address two key safety concerns: the risk of circulating vaccine-derived poliovirus (cVDPV) outbreaks triggered by conventional oral poliovirus vaccines (OPVs), and the biosafety risk associated with live virus used in conventional inactivated poliovirus vaccine (IPV) production. This article reviews the research progress in novel oral poliovirus vaccines (nOPV), S19-inactivated poliovirus vaccine (S19-IPV), and virus-like particle (VLP) vaccines. It is recommended that multi-technology synergy be adopted to advance technical upgrades from genetic modification to zero-live-virus production, thereby establishing a robust immune barrier free of derivative risks and achieving complete polio eradication.

Key words: Poliomyelitis, Poliovirus Vaccine, Novel Oral Poliovirus Vaccine (nOPV), S19 Strain, Virus-Like Particle (VLP)vaccine, Vaccine-Derived Poliovirus (VDPV)

CLC Number:

R186
R994.11

Quan Yaru, Zhang Su, Chen Guoqing. Progress in vaccine development during the endgame of the Global Polio Eradication Initiative[J]. Chinese Journal of Pharmacovigilance, 2026, 23(8): 948-953.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20260303

https://zgywjj.magtechjournal.com/EN/Y2026/V23/I8/948

References

[1] Mohanty A, Rohilla R, Zaman K, et al.Vaccine derived poliovirus (VDPV)[J]. Infez Med, 2023, 31(2): 174-185.
[2] Sabin A B.Present status of attenuated live virus poliomyelitis vaccine[J]. Bull N Y Acad Med, 1957, 33(1): 17-39.
[3] Devaux C A, Pontarotti P, Levasseur A, et al.Is it time to switch to a formulation other than the live attenuated poliovirus vaccine to prevent poliomyelitis?[J]. Front Public Health, 2023, 11: 1284337.
[4] WHO. Polio eradication strategy2022-2026: delivering on a promise [EB/OL]. (2021-06-09)[2026-04-03]. https://www.who.int/publications/i/item/9789240031937.
[5] Peak C M, Lyons H, Voorman A, et al.Monitoring the risk of type-2 circulating vaccine-derived poliovirus emergence during roll-out of type-2 novel oral polio vaccine[J]. Vaccines, 2024, 12(12): 1308.
[6] Kettlitz R, Harries M, Contreras S, et al.Self-reported poliomyelitis vaccination and documentation in adults indicates high uptake: a digital german epidemic panel, december 2024[J]. BMC Public Health, 2025, 25(1): 3514.
[7] Kramarov S, Palatna L, Shpak I, et al.Acute transverse myelitis in a child following oral live polio vaccine administration[J]. Int Med Case Rep J, 2025, 18: 899-907.
[8] Platt L R, Estívariz C F, Sutter R W.Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden[J]. J Infect Dis, 2014, 210(Suppl 1): 380-389.
[9] Liu Q, Liu Z, Huang B, et al.Global trends in poliomyelitis research over the past 20 years: a bibliometric analysis[J]. Hum Vaccin Immunother, 2023, 19(1): 2173905.
[10] Candido D D S, Dellicour S, Cooper L V, et al. Historical and current spatiotemporal patterns of wild and vaccine-derived poliovirus spread[J]. Nat Microbiol, 2025, 10(12): 3148-3161.
[11] WHO. Statement of the forty-fourth meeting of the polio IHR emergency committee[EB/OL]. (2026-03-04)[2026-04-06]. https://www.who.int/news/item/04-03-2026-statement-of-the-forty-fourth-meeting-of-the-polio-ihr-emergency-committee.
[12] Thompson K M, Lauring A S, Pollard A J, et al.Polio eradication: addressing the hurdles on the last mile[J]. Cell, 2023, 186(1): 1-4.
[13] Ehrenfeld E, Modlin J, Chumakov K.Future of polio vaccines[J]. Expert Rev Vaccines, 2009, 8(7): 899-905.
[14] Mbani C J, Nekoua M P, Moukassa D, et al.The fight against poliovirus is not over[J]. Microorganisms, 2023, 11(5): 1323.
[15] Kumar P, Bird C, Holland D, et al.Current and next-generation formulation strategies for inactivated polio vaccines to lower costs, increase coverage, and facilitate polio eradication[J]. Hum Vaccin Immunother, 2022, 18(7): 2154100.
[16] Wassilak S G F, Mohamed A, Bigouette J P. Impediments to progress toward polio eradication during 2014-2024: effectively addressing the current challenges[J]. Vaccines, 2025, 13(10): 1060.
[17] Wahid R, Mercer L, Gast C, et al.Evaluating stability of attenuated sabin and two novel type 2 oral poliovirus vaccines in children[J]. NPJ Vaccines, 2022, 7(1): 19.
[18] Svitkin Y V, Maslova S V, Agol V I.The genomes of attenuated and virulent poliovirus strains differ in their in vitro translation efficiencies[J]. Virology, 1985, 147(2): 243-252.
[19] Macadam A J, Stone D M, Almond J W, et al.The 5' noncoding region and virulence of poliovirus vaccine strains[J]. Trends Microbiol, 1994, 2(11): 449-454.
[20] Moss E G, O’Neill R E, Racaniello V R. Mapping of attenuating sequences of an avirulent poliovirus type 2 strain[J]. J Virol, 1989, 63(5): 1884-1890.
[21] Avanzino B C, Jue H, Miller C M, et al.Molecular mechanism of poliovirus sabin vaccine strain attenuation[J]. J Biol Chem, 2018, 293(40): 15471-15482.
[22] Quarleri J.Poliomyelitis is a current challenge: long-term sequelae and circulating vaccine-derived poliovirus[J]. GeroScience, 2023, 45(2): 707-717.
[23] Wahid R, Mercer L, Macadam A, et al.Assessment of genetic changes and neurovirulence of shed sabin and novel type 2 oral polio vaccine viruses[J]. NPJ Vaccines, 2021, 6(1): 94.
[24] Kalkowska D A, Wassilak S G F, Pallansch M A, et al. Outbreak response strategies with type 2-containing oral poliovirus vaccines[J]. Vaccine, 2023, 41(Suppl 1): A142-A152.
[25] Yeh M T, Bujaki E, Dolan P T, et al. Engineering the live-attenuated polio vaccine to prevent reversion to virulence[J]. Cell Host Microbe, 2020, 27(5): 736-751.e8.
[26] Yeh M T, Smith M, Carlyle S, et al.Genetic stabilization of attenuated oral vaccines against poliovirus types 1 and 3[J]. Nature, 2023, 619(7968): 135-142.
[27] Kurji F D, Bandyopadhyay A S, Zipursky S, et al.Novel oral polio vaccine type 2 use for polio outbreak response: a global effort for a global health emergency[J]. Pathogens, 2024, 13(4): 273.
[28] Mercer L D, Seña A C, Colgate E R, et al.Safety and immunogenicity of novel live attenuated type 1 and type 3 oral poliomyelitis vaccines in healthy adults in the USA: a first-in-human, observer-masked, multicentre, phase 1 randomised controlled trial[J]. Lancet Infect Dis, 2025, 25(12): 1363-1376.
[29] Vumbi S. Polio Eradication Strategy2022-2026: delivering on a promise, extension to 2029[R/OL]. 2025-08-26. https://www.who.int/publications/i/item/9789240109506.
[30] Bricks L F, Macina D, Vargas-Zambrano J C. Polio epidemiology: strategies and challenges for polio eradication post the COVID-19 pandemic[J]. Vaccines, 2024, 12(12): 1323.
[31] Deng Y, Leng Y, Liu J, et al.Safety evaluation of inactivated poliomyelitis vaccine[J]. Hum Vaccin Immunother, 2026, 22(1): 2620273.
[32] Sutter R W, Eisenhawer M, Molodecky N A, et al.Inactivated poliovirus vaccine: recent developments and the tortuous path to global acceptance[J]. Pathogens, 2024, 13(3): 224.
[33] Jacobson M F, Baltimore D.Polypeptide cleavages in the formation of poliovirus proteins[J]. Proc Natl Acad Sci U S A, 1968, 61(1): 77-84.
[34] Basavappa R, Syed R, Flore O, et al.Role and mechanism of the maturation cleavage of VP0 in poliovirus assembly: structure of the empty capsid assembly intermediate at 2.9 a resolution[J]. Protein Sci, 1994, 3(10): 1651-1669.
[35] Sherry L, Grehan K, Snowden J S, et al.Comparative molecular biology approaches for the production of poliovirus virus-like particles using pichia pastoris[J]. mSphere, 2020, 5(2): e00838-19.
[36] Mohsen M O, Zha L, Cabral-Miranda G, et al.Major findings and recent advances in virus-like particle (VLP)-based vaccines[J]. Semin Immunol, 2017, 34: 123-132.
[37] Han T, Xiao J, Zhang S, et al.Research progress towards poliovirus virus-like particle vaccines: a review[J]. Vaccines, 2026, 14(3): 216.
[38] Ren M, Abdullah S W, Pei C, et al.Use of virus-like particles and nanoparticle-based vaccines for combating picornavirus infections[J]. Vet Res, 2024, 55(1): 128.
[39] Hong Q, Wang S, Wang X, et al.Vaccine potency and structure of yeast-produced polio type 2 stabilized virus-like particles[J]. Vaccines, 2024, 12(9): 1077.
[40] Sherry L, Grehan K, Bahar M W, et al.Production of an immunogenic trivalent poliovirus virus-like particle vaccine candidate in yeast using controlled fermentation[J]. NPJ Vaccines, 2025, 10(1): 64.